for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bausch Health Companies Inc

BHC.TO

Latest Trade

38.57CAD

Change

0.41(+1.07%)

Volume

614,334

Today's Range

37.86

 - 

38.62

52 Week Range

23.60

 - 

38.62

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
38.16
Open
38.51
Volume
614,334
3M AVG Volume
15.68
Today's High
38.62
Today's Low
37.86
52 Week High
38.62
52 Week Low
23.60
Shares Out (MIL)
352.43
Market Cap (MIL)
13,593.27
Forward P/E
6.67
Dividend (Yield %)
--

Next Event

Q4 2019 Bausch Health Companies Inc Earnings Release

Latest Developments

More

Bausch Health Companies Posts Q3 Loss Per Share $0.14

Bausch Health Licenses Clearside Biomedical's Xipere, An Investigational Treatment For Macular Edema Associated With Uveitis

Bausch Health Co ‍Announces U.S. Launch Of Preservision Areds 2 Formula Minigel Eye Vitamins​

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bausch Health Companies Inc

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Industry

Biotechnology & Drugs

Contact Info

2150 Saint-Elzear Blvd W

+1.514.7446792

https://www.bauschhealth.com

Executive Leadership

Joseph C. Papa

Chairman of the Board, Chief Executive Officer

Paul S. Herendeen

Chief Financial Officer, Executive Vice President

Thomas J. Appio

President & Co-Head Bausch + Lomb/International

Joseph F. Gordon

President & Co-Head Bausch + Lomb/International

William Douglas Humphries

President of Ortho-Dermatologics

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

9.7K

2017

8.7K

2018

8.4K

2019(E)

8.6K
EPS (USD)

2016

5.470

2017

3.830

2018

3.970

2019(E)

4.352
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.21
Price To Book (MRQ)
4.13
Price To Cash Flow (TTM)
6.74
Total Debt To Equity (MRQ)
949.48
LT Debt To Equity (MRQ)
945.45
Return on Investment (TTM)
-2.12
Return on Equity (TTM)
-1.86

Latest News

Latest News

Pharmacy chains sue Bausch Health, other drugmakers for overcharging for diabetes drug

Three pharmacy chains, including Walgreens Boots Alliance, have filed a lawsuit against drugmakers Bausch Health Inc, Assertio Therapeutics and Lupin Ltd, seeking damages for overcharging for Bausch's diabetes drug Glumetza.

Convictions of ex-Valeant and Philidor executives are upheld, payouts reduced

A U.S. appeals court on Thursday upheld the convictions of two drug industry executives for defrauding Valeant Pharmaceuticals International Inc through a multimillion-dollar kickback scheme, but reduced how much they must forfeit for their crimes.

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.

Bausch Health's lotion for plaque psoriasis wins FDA approval

The U.S. Food and Drug Administration on Thursday approved Bausch Health Companies Inc's topical plaque psoriasis treatment, which is expected to be a key revenue driver for the company.

Bausch Health's lotion for plaque psoriasis wins FDA approval

Bausch Health Companies Inc said on Thursday the U.S. Food and Drug Administration has approved its lotion for plaque psoriasis in adults.

Court gives bankrupt drugmaker Synergy green light to advance sale

Synergy Pharmaceuticals Inc, a bankrupt developer of gastrointestinal therapies, has received court approval to proceed with a plan to sell itself, with Bausch Health Companies Inc serving as a so-called stalking horse bidder.

Ex-Valeant, Philidor executives get prison for fraud

A former executive at Valeant Pharmaceuticals International Inc and the former head of a start-up mail-order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme.

Ex-Valeant, Philidor executives get prison for fraud

A former executive at Valeant Pharmaceuticals International Inc and the former head of a start-up mail-order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme.

Bausch Health's plaque psoriasis lotion gets tentative FDA approval

Bausch Health Cos Inc, formerly Valeant Pharmaceuticals, said on Monday it received tentative U.S. approval to market its plaque psoriasis lotion, Bryhali.

Bausch Health's plaque psoriasis lotion gets tentative FDA approval

Bausch Health Cos said on Monday it received tentative approval from the U.S. health regulator to market its plaque psoriasis lotion, Bryhali.

Bausch Health unit moves to settle charges it misled investors -SEC

Salix Pharmaceuticals, a unit of Bausch Health Companies Inc <BHC.TO>, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

Bausch Health subsidiary moves to settle charges it misled investors -SEC

Salix Pharmaceuticals, a unit of Bausch Health Companies Inc, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

UPDATE 2-Bausch Health beats profit estimates, promises to cut debt

* Toronto shares rise 6 pct; New York shares 7.5 pct (Adds details from conference call, analyst comment, updates share price)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up